AEterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at

Share Name	Share Symbol	Market	Type
Aeterna Zentaris Inc	NASDAQ:AEZS	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.0642	0.75%	8.65	8.52	8.67	8.6799	8.50	8.50	735	15:35:12

Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Aeterna Zentaris Charts.

Updated results from Phase 2 clinical trial of perifosine in combination with capecitabine for the treatment of metastatic colon cancer to be presented on Sunday, January 24, 2010 QUEBEC CITY, Jan. 21 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that updated results from a Phase 2 clinical trial of perifosine (KRX-0401) in combination with capecitabine conducted by its partner and licensee for this compound in the United States, Canada and Mexico, Keryx Biopharmaceuticals Inc. ("Keryx") (NASDAQ:KERX), has been selected for poster presentation at the upcoming American Society of Clinical Oncology ("ASCO") 2010 Gastrointestinal Cancers Symposium, to be held in Orlando, Florida from January 22-24, 2010. The clinical data to be presented demonstrates the potential safety and efficacy of perifosine in the treatment of patients with metastatic colon cancer. Details on the poster presentation are as follows: Abstract #447 Title: "A Randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colon cancer (mCRC): updated results." Lead Author: Johanna Bendell, MD Session Name: General Poster Session C: Cancers of the Colon and Rectum Date: Sunday, January 24, 2010 Presentation Time: 7:00 AM- 8:00 AM; 12:00 NOON-1:00PM A copy of the above referenced abstract can be viewed online through ASCO's website, http://www.asco.org/. About AEterna Zentaris Inc. AEterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at http://www.aezsinc.com/. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law. DATASOURCE: AETERNA ZENTARIS INC. CONTACT: Investor Relations: Dennis Turpin, SVP and CFO, (418) 652-8525 ext. 242, ; Media Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext. 406,

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AEZS Aeterna Zentaris Inc